Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 220,298
  • Shares Outstanding, K 133,514
  • Annual Sales, $ 21,190 K
  • Annual Income, $ -203,540 K
  • 60-Month Beta 2.36
  • Price/Sales 10.58
  • Price/Cash Flow N/A
  • Price/Book 4.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.42
  • Number of Estimates 1
  • High Estimate -0.42
  • Low Estimate -0.42
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.48 +12.84%
on 10/14/19
1.78 -6.18%
on 10/16/19
+0.10 (+6.37%)
since 10/11/19
3-Month
1.39 +20.14%
on 10/11/19
2.91 -42.61%
on 10/07/19
-0.47 (-21.96%)
since 08/09/19
52-Week
1.39 +20.14%
on 10/11/19
6.50 -74.31%
on 03/22/19
-2.00 (-54.50%)
since 11/09/18

Most Recent Stories

More News
Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento's research team will participate in upcoming industry conferences in...

SRNE : 1.67 (+1.21%)
The Expanding CBD Market Begins to Witness Thawing Regulations

As the cannabis industry continues to develop, lawmakers and federal agencies are actively working towards expanding the market. Recently, U.S. Department of Agriculture (USDA) revealed new hemp regulations...

NLBIF : 0.3151 (-1.93%)
NLB.CN : 0.395 (-5.95%)
VGWCF : 2.6350 (+3.33%)
VGW.VN : 3.490 (+3.25%)
SRNE : 1.67 (+1.21%)
ITHUF : 1.4400 (-1.88%)
IAN.CN : 1.870 (-3.11%)
CBWTF : 0.5521 (-5.20%)
XLY.VN : 0.740 (-2.63%)
Earnings Preview: Sorrento Therapeutics (SRNE) Q3 Earnings Expected to Decline

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRNE : 1.67 (+1.21%)
Easing Regulations Thrust CBD into Consumer Focus

As the legal cannabis industry continues to permeate throughout the globe, more and more consumers are beginning to try products within the marketplace. Notably, cannabidiol or CBD is one of the fastest-growing...

SDEC : 0.0601 (-14.02%)
NEPT : 2.95 (-16.67%)
NEPT.TO : 3.90 (-17.37%)
SRNE : 1.67 (+1.21%)
PLNHF : 1.5641 (+11.72%)
PLTH.CN : 2.080 (+9.47%)
CBWTF : 0.5521 (-5.20%)
XLY.VN : 0.740 (-2.63%)
CBD Use Trends Upward as Regulators Soften Stance

Cannabidiol, or CBD, has become the latest craze among health-conscious consumers. Specifically, consumers in the North American region are purchasing hemp-derived CBD products for health and wellness...

NLBIF : 0.3151 (-1.93%)
NLB.CN : 0.395 (-5.95%)
APHA : 4.97 (-1.97%)
APHA.TO : 6.54 (-2.97%)
SRNE : 1.67 (+1.21%)
ITHUF : 1.4400 (-1.88%)
IAN.CN : 1.870 (-3.11%)
CBWTF : 0.5521 (-5.20%)
XLY.VN : 0.740 (-2.63%)
Los Angeles Court Rejects Patrick Soon-Shiong's Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong's attempt to allow him and his company, NantPharma, to avoid...

SRNE : 1.67 (+1.21%)
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable...

SRNE : 1.67 (+1.21%)
Sorrento Therapeutics Announces $25 Million Registered Direct Offering

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable...

SRNE : 1.67 (+1.21%)
SmarTrend Watching for Potential Pullback in Shares of Sorrento Therape After 6.49% Gain

Sorrento Therape (NASDAQ:SRNE) traded in a range yesterday that spanned from a low of $2.46 to a high of $2.91. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of...

SRNE : 1.67 (+1.21%)
Scilex Announces New Medicaid Agreements with CA & FL

Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its subsidiary, Scilex Pharmaceuticals, Inc., (together, with Scilex...

SRNE : 1.67 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SRNE with:

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

2nd Resistance Point 1.73
1st Resistance Point 1.70
Last Price 1.67
1st Support Level 1.62
2nd Support Level 1.57

See More

52-Week High 6.50
Fibonacci 61.8% 4.55
Fibonacci 50% 3.94
Fibonacci 38.2% 3.34
Last Price 1.67
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar